Sanofi’s lunsekimig, a novel bispecific Nanobody® VHH, has successfully met its primary and key secondary endpoints in two Phase 2 clinical trials targeting asthma and chronic rhinosinusitis with nasal polyps. The AIRCULES Phase 2b study demonstrated a statistically significant reduction in asthma exacerbations and improved pulmonary function in patients with moderate to severe asthma, while the DUET Phase 2a study showed significant improvements in nasal polyp scores and congestion in patients with chronic rhinosinusitis. Both studies reported a favorable safety profile for lunsekimig, with common adverse events being manageable.

The significance of these findings lies in lunsekimig’s dual mechanism of action, targeting both thymic stromal lymphopoietin (TSLP) and interleukin-13 (IL-13), which are key contributors to inflammation and tissue damage in respiratory diseases. In the AIRCULES study, the primary endpoint was achieved with a notable improvement in forced expiratory volume (FEV1), indicating that lunsekimig could address the unmet medical need for effective asthma management, particularly in patients who remain uncontrolled despite existing therapies. The DUET study further reinforces lunsekimig’s potential to alleviate symptoms associated with chronic rhinosinusitis, which frequently co-occurs with asthma.

The takeaway from these studies is the potential shift in therapeutic strategies for managing chronic respiratory conditions. Lunsekimig’s unique dual-targeting approach may pave the way for more effective treatments that not only reduce exacerbations but also improve overall patient quality of life. As lunsekimig progresses into further clinical trials, including ongoing Phase 2 and upcoming Phase 3 studies, its development could significantly impact the timelines for new therapeutic options in the respiratory disease landscape, potentially accelerating the pathway to regulatory approval and clinical adoption.

Source: globenewswire.com